Evaluation of the clinical efficacy and safety of nitric oxide synthesized from room air in the postoperative period of cardiac surgery

Background. Inhaled nitric oxide is a highly selective pulmonary vasodilator, the potential benefits of which include reduced resistance and pressure in the pulmonary artery without systemic arterial hypotension, vasodilation in well-ventilated areas of the lungs, rapid onset of action, and a fairly low incidence of side effects in the therapeutic dose range. Objective. Тс estimate the clinical efficacy and safety of the method for synthesizing nitric oxide from room air in the postoperative period of cardiac surgery. Design and methods. A total of 110 patients were enrolled in the study: 55 patients were included in the main group (nitric oxide was synthesized from room air by AIT-NO-01 device), 55 patients were enrolled in the retrospective control group (nitric oxide was inhaled from the balloon). Inclusion criteria were: undergone heart surgery, mean pulmonary artery pressure (PAPm) ≥ 25 mm Hg., pulmonary artery wedge pressure (PAWP) ≤ 15 mm Hg. Results. After one hour of nitric oxide inhalation in the main group, there were a 35 % decrease in PVR and a 16 % decrease in PAPm. In the control group, there were a decrease in PVR by 40 % and decrease in PAPm by 19 %. Inhalation of nitric oxide did not affect the systemic circulation hemodynamics both in the main and in the control groups. The median duration of the mechanical ventilation (MV) was 7.3 (4.5; 13.8) h and the median length of stay (LOS) in the ICU was 23.2 (21.3; 46) h in the main group. In the retrospective control group, the median duration of MV was 8.2 (5; 14.1) h, and the length of ICU stay was 24 (22; 45.3) h; found no differences between the groups. Conclusion. Nitric oxide synthesized from room air significantly reduces PVR and PAPm in patients with precapillary pulmonary hypertension after cardiac surgery. There were no significant differences in the effect on a pulmonary circulation, clinical data and side effects between the methods of synthesis of nitric oxide from room air and dosing from balloons.

1. Mubeen M, Singh AK, Agarwal SK, et al. Mitral valve replacement in severe pulmonary arterial hypertension. Asian Cardiovasc Thorac Ann. 2008; 16 (1): 37-42. DOI: 10.1177/021849230801600110.

2. Enter DH, Zaki A, Duncan BF, et al. A contemporary analysis of pulmonary hypertension in patients undergoing mitral valve surgery: Is this a risk factor? J Thorac Cardiovasc Surg. 2016; 151 (5): 1288-1299. DOI: 10.1016/j.jtcvs.2015.12.063.

3. Borde DP, Asegaonkar B, Khade S, et al. Impact of preoperative pulmonary arterial hypertension on early and late outcomes in patients undergoing valve surgery for rheumatic heart disease. Indian J Anaesth. 2018; 62 (12): 963-971. DOI: 10.4103/ija.IJA_374_18.

4. Galie N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016; 37 (1): 67119. DOI: 10.1093/eurheartj/ehv317.

5. Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail. 2013; 1 (4): 290-299. DOI: 10.1016/j.jchf.2013.05.001.

6. Leung CC, Moondra V, Catherwood E, et al. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol. 2010; 106 (2): 284-286. DOI: 10.1016/j.amjcard.2010.02.039.

7. Miceli A, Varone E, Gilmanov D, et al. Impact of pulmonary hypertension on mortality after operation for isolated aortic valve stenosis. Int J Cardiol. 2013; 168 (4): 3556-3559. DOI: 10.1016/j.ijcard.2013.05.001.

8. Hart SA, Krasuski RA, Wang A, et al. Pulmonary hypertension and elevated transpulmonary gradient in patients with mitral stenosis. J Heart Valve Dis. 2010; 19 (6): 708-715.

9. Goldstone AB, Chikwe J, Pinney SP, et al. Incidence, epidemiology, and prognosis of residual pulmonary hypertension after mitral valve repair for degenerative mitral regurgitation. Am J Cardiol. 2011; 107 (5): 755-760. DOI: 10.1016/j.amjcard.2010.10.057.

10. Walls MC, Cimino N, Bolling SF, et al. Persistent pulmonary hypertension after mitral valve surgery: does surgical procedure affect outcome? J Heart Valve Dis. 2008; 17 (1): 1-9.

11. Bautin AE, Ksendikova AV, Yakovlev AS, et al. Anesthetic management and intensive care in the patients with pulmonary hypertension associated with left heart diseases. Messenger of Anesthesiology and Resuscitation. 2019; 16 (3): 33-40. DOI: 10.21292/2078-5658-201916-3-33-40. In Russian

12. Fernandes JL, Sampaio RO, Brandao CM, et al. Comparison of inhaled nitric oxide versus oxygen on hemodynamics in patients with mitral stenosis and severe pulmonary hypertension after mitral valve surgery. Am J Cardiol. 2011; 107 (7): 1040-1045. DOI: 10.1016/j.amjcard.2010.11.030.

13. Fattouch K, Sbraga F, Bianco G et al. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg. 2005; 20 (2): 171-176. DOI: 10.1111/j.0886-0440.2005.200383w.x.

14. Winterhalter М, Rex S, Stoppe C, et al. Effect of iloprost inhalation on postoperative outcome in high-risk cardiac surgical patients: a prospective randomized-controlled multicentre trial (ILOCARD). Can J Anaesth. 2019; 66 (8): 907-920. DOI: 10.1007/s12630-019-01309-8.

15. Kozlov IA, Romanov AA, Dzybinskaya, et al. Inhaled Nitric Oxide for the Prevention of Impaired Arterial Oxygenation during Myocardial Revascularization with Extracorporeal Circulation. General Reanimatology. 2011; 7 (1): 31-35. In Russian

16. Pichugin VV, Domnin SE, Kalinina ML, et al. Intraoperative NO-therapy in patients with high pulmonary hypertension for the correction of valvular heart disease. Medical almanac. 2017; 3 (48): 144-149. In Russian [

17. Bautin AE, Osovskikh VV. Acute right ventricular failure. Messenger of Anesthesiology and Resuscitation. 2018; 15 (5): 74-86. DOI: 10.21292/2078-5658-2018-155-74-86. In Russian

18. Frostell CG, Blomqvist H, Hedenstierna G, et al. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. Anesthesiology. 1993; 78 (3): 427-435. DOI: 10.1097/00000542-199303000-00005.

19. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991; 338 (8776): 1173-1174. DOI: 10.1016/0140-6736(91)92033-x.

20. Kozlov I. A., Poptsov V. N. Clinical use of inhaled nitric oxide. Anesteziologiya i reanimatologiya. 1997; 5: 80-85. In Russian

21. Germann P, Braschi A, Della Rocca G, et al. Inhaled nitric oxide therapy in adults: European expert recommendations. Intensive Care Med. 2005; 31 (8): 10291041. DOI: 10.1007/s00134-005-2675-4.

22. Binglan Yu, Muenster S, Blaesi AH, et al. Producing nitric oxide by pulsed electrical discharge in air for portable inhalation therapy. Sci Transl Med. 2015; 7 (294): 294ra107. DOI: 10.1126/scitranslmed.aaa3097.

23. Buranov SN, Karelin VI, Selemir VD, et al. Inhalation NO-therapy machine. Pribory i tekhnika ehksperimenta. 2019; 5: 158-159. In Russian